English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The aim of the present study was to investigate the effect of microRNA (miR)-92a on cystatin C expression in patients with type II diabetes and lower limb ischemia. A total of 199 patients diagnosed with type II diabetes were included in the study and divided into three experimental groups: Simple type II diabetes mellitus (T2DM; n=60) group; type II diabetes with light to moderate occlusion (LLI-LM; n=70) group; and the type II diabetes with severe occlusion (LLI-S; n=69) group according to the patient ankle-brachial index score. In addition, 60 healthy individuals were examined as a control population. The expression levels of various biochemical indices were detected, including cystatin C in the peripheral blood. The expression levels of miR-92a and cystatin C mRNA were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and the correlation between miR-92a, cystatin C and the pathological development of type II diabetic lower limb ischemia was analyzed. The protein expression levels of cystatin C were detected using western blot analysis. Bioinformatic analysis indicated that miR-92a was able to downregulate cystatin C expression, and this result was supported by endothelial cell transfection. In the transfection assay, an miR-92a mimic downregulated cystatin C expression, while an miR-92a inhibitor upregulated cystatin C expression. The results of the RT-qPCR indicated that the expression levels of miR-92a in the LLI-S group were reduced compared with those in the T2DM and LLI-LM groups, and significantly lower compared with those in the negative control group. Platelet-derived miR-92a appeared to downregulate cystatin C expression in patients with type II diabetes and lower limb ischemia. Therefore, the combined detection of miR-92a and cystatin C may be useful as a method for clinically screening patients with type II diabetes for lower limb ischemia.

Platelet-derived miR-92a downregulates cysteine protease inhibitor cystatin C in type II diabetic lower limb ischemia